Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Capital Expenditures: 2018-2025

Historic Capital Expenditures for Autolus Therapeutics (AUTL) over the last 3 years, with Sep 2025 value amounting to $4.4 million.

  • Autolus Therapeutics' Capital Expenditures fell 54.03% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.0 million, marking a year-over-year increase of 149.52%. This contributed to the annual value of $22.1 million for FY2024, which is 100.94% up from last year.
  • Latest data reveals that Autolus Therapeutics reported Capital Expenditures of $4.4 million as of Q3 2025, which was down 39.43% from $7.3 million recorded in Q2 2025.
  • Over the past 5 years, Autolus Therapeutics' Capital Expenditures peaked at $11.1 million during Q4 2024, and registered a low of $555,000 during Q1 2024.
  • Moreover, its 3-year median value for Capital Expenditures was $4.3 million (2023), whereas its average is $4.8 million.
  • In the last 5 years, Autolus Therapeutics' Capital Expenditures tumbled by 84.97% in 2024 and then surged by 1,385.23% in 2025.
  • Autolus Therapeutics' Capital Expenditures (Quarterly) stood at $633,000 in 2022, then spiked by 133.33% to $1.5 million in 2023, then soared by 652.34% to $11.1 million in 2024, then slumped by 54.03% to $4.4 million in 2025.
  • Its last three reported values are $4.4 million in Q3 2025, $7.3 million for Q2 2025, and $8.2 million during Q1 2025.